The attractive value proposition for our compound is:
- NeuMedics authored and was issued a patent for NM108 and it’s derivatives.
- It may be the only drug product currently in development in the US that is an eye-drop to treat DME.
- It has a different mechanism-of-action than all other existing therapies.
- It is absorbed by the eye, making eye injections unnecessary.
- It is the only drug that targets inflammation inside the eye that leads to DME.
- It can be used for first line treatment of early disease and may preclude the need for injections ever becoming necessary in the future.
- It could be used concomitantly with anti-VEGF injections to reduce the frequency of their administration.